161 related articles for article (PubMed ID: 16185555)
1. [Favorable outcome of Castleman's disease treated with oral valganciclovir].
Valencia ME; Moreno V; Martínez P; Casado I
Med Clin (Barc); 2005 Sep; 125(10):399. PubMed ID: 16185555
[No Abstract] [Full Text] [Related]
2. Multicentric Castleman's disease as a cause for unclear febrile episodes in a 55-year-old HIV-infected man.
Lederer H; Achermann Y; Tinguely M; Stenner F; Fehr J
Infection; 2012 Apr; 40(2):203-5. PubMed ID: 21837451
[TBL] [Abstract][Full Text] [Related]
3. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.
Uldrick TS; Polizzotto MN; Aleman K; O'Mahony D; Wyvill KM; Wang V; Marshall V; Pittaluga S; Steinberg SM; Tosato G; Whitby D; Little RF; Yarchoan R
Blood; 2011 Jun; 117(26):6977-86. PubMed ID: 21487108
[TBL] [Abstract][Full Text] [Related]
4. Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient.
Murphy C; Hawkes E; Chionh F; Chong G
J Clin Pharm Ther; 2017 Feb; 42(1):111-114. PubMed ID: 27790727
[TBL] [Abstract][Full Text] [Related]
5. [HHV 8 positive Castleman's disease and auto-immune neutropenia in 2 HIV-infected patients].
Aaron L; Kahn JE; Therby A; Lidove O; Zucman D; Viard JP
Rev Med Interne; 2003 Nov; 24(11):748-52. PubMed ID: 14604753
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
Ramaswami R; Lurain K; Peer CJ; Serquiña A; Wang V; Widell A; Goncalves P; Steinberg SM; Marshall V; George J; Figg WD; Whitby D; Ziegelbauer J; Uldrick TS; Yarchoan R
Blood; 2020 Jun; 135(25):2316-2319. PubMed ID: 32276276
[No Abstract] [Full Text] [Related]
7. Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(-) EBV(-) HHV8(+) patient.
Ozbalak M; Tokatlı I; Özdemirli M; Tecimer T; Ar MC; Örnek S; Koroglu A; Laleli Y; Ferhanoglu B
Eur J Haematol; 2013 Nov; 91(5):467-9. PubMed ID: 23865480
[TBL] [Abstract][Full Text] [Related]
8. New approaches to the treatment of human herpesvirus 8-associated disease.
Casper C
Rev Med Virol; 2008; 18(5):321-9. PubMed ID: 18615774
[TBL] [Abstract][Full Text] [Related]
9. Valganciclovir in an HIV-infected patient with Castleman's disease.
Marque AS; Sequeira C; Antunes P
Med Clin (Barc); 2020 Oct; 155(8):369-370. PubMed ID: 31488261
[No Abstract] [Full Text] [Related]
10. Successful treatment and durable remission of human herpesvirus-8-induced Kaposi sarcoma and multicentric Castleman's disease under valganciclovir in an HIV-negative patient.
Plachouri KM; Oikonomou C; Sarantopoulos A; Koumoundourou D; Georgiou S; Spiliopoulos T
Dermatol Ther; 2020 May; 33(3):e13419. PubMed ID: 32297410
[No Abstract] [Full Text] [Related]
11. HIV-associated multicentric Castleman disease.
Oksenhendler E
Curr Opin HIV AIDS; 2009 Jan; 4(1):16-21. PubMed ID: 19343828
[TBL] [Abstract][Full Text] [Related]
12. HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease.
Sbenghe MM; Besa E; Mahipal A; Dulau Florea A; Bray P; Caro J
Oncologist; 2012; 17(1):145-6; author reply 147-8. PubMed ID: 22286773
[TBL] [Abstract][Full Text] [Related]
13. Multicentric Castleman's disease in 2 patients with HIV infection, unresponsive to antiviral therapy.
Bottieau E; Colebunders R; Schroyens W; Van Droogenbroeck J; De Droogh E; Depraetere K; De Raeve H; Van Marck E
Acta Clin Belg; 2000; 55(2):97-101. PubMed ID: 10881375
[TBL] [Abstract][Full Text] [Related]
14. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease.
Powles T; Stebbing J; Montoto S; Nelson M; Gazzard B; Orkin C; Webb A; Bower M
Blood; 2007 Dec; 110(12):4132-3. PubMed ID: 18024800
[No Abstract] [Full Text] [Related]
15. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
Uldrick TS; Polizzotto MN; Yarchoan R
Curr Opin Oncol; 2012 Sep; 24(5):495-505. PubMed ID: 22729151
[TBL] [Abstract][Full Text] [Related]
16. Multicentric Castleman's disease: an emerging opportunistic infection.
McCall J; Phillips JC
J Assoc Nurses AIDS Care; 2013; 24(1):88-90. PubMed ID: 22564919
[No Abstract] [Full Text] [Related]
17. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.
Uldrick TS; Polizzotto MN; Aleman K; Wyvill KM; Marshall V; Whitby D; Wang V; Pittaluga S; O'Mahony D; Steinberg SM; Little RF; Yarchoan R
Blood; 2014 Dec; 124(24):3544-52. PubMed ID: 25331113
[TBL] [Abstract][Full Text] [Related]
18. [Tocilizumab treatment of HHV8-positive/HIV-negative, multricentric plasma cell type Castleman's disease].
Mûzes G; Csomor J; Sipos F
Magy Onkol; 2016 Nov; 60(4):328-332. PubMed ID: 27898752
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous Kaposi's sarcoma and Castleman's disease in a HIV-negative patient. Response to rituximab and doxorubicin.
García-Arpa M; Calle-Primo C; Martín-Dávila F
Med Clin (Barc); 2020 Dec; 155(12):565-566. PubMed ID: 31759694
[No Abstract] [Full Text] [Related]
20. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
Mylona EE; Baraboutis IG; Lekakis LJ; Georgiou O; Papastamopoulos V; Skoutelis A
AIDS Rev; 2008; 10(1):25-35. PubMed ID: 18385778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
